The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Liver disease encompasses pathologies as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcohol liver disease, hepatocellular carcinoma, viral hepatitis, and autoimmune hepatitis. Nowadays, underlying mechanisms associating gut permeability and liver disease development are not well understood, although evidence points to the involvement of intestinal microbiota and their metabolites. Animal studies have shown alterations in Toll-like receptor signaling related to the leaky gut syndrome by the action of bacterial lipopolysaccharide. In humans, modifications of the intestinal microbiota in intestinal permeability have also been related to liver disease. Some of these changes were observed in bacterial species belonging Roseburia, Streptococcus, and Rothia. Currently, numerous strategies to treat liver disease are being assessed. This review summarizes and discusses studies addressed to determine mechanisms associated with the microbiota able to alter the intestinal barrier complementing the progress and advancement of liver disease, as well as the main strategies under development to manage these pathologies. We highlight those approaches that have shown improvement in intestinal microbiota and barrier function, namely lifestyle changes (diet and physical activity) and probiotics intervention. Nevertheless, knowledge about how such modifications are beneficial is still limited and specific mechanisms involved are not clear. Thus, further in-vitro, animal, and human studies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases
Pedersen, B. K., & Saltin, B. (2015) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/sms.12581 · Cited by 3,514
Formation of propionate and butyrate by the human colonic microbiota
Louis, P., & Flint, H. J. (2017) · Environmental Microbiology · doi:10.1111/1462-2920.13589 · Cited by 3,028 · cited 1×
“Acetate is an important product of carbohydrate fermentation of most anaerobic bacteria, whereas propionic and butyric acids are produced from carbohydrate or protein fermentation through a different subdivision of bacteria [40,41].”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
The Long-Term Stability of the Human Gut Microbiota
Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., Clemente, J. C., Knight, R., Heath, A. C., Leibel, R. L., et al. (2013) · Science · doi:10.1126/science.1237439 · Cited by 2,058
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · cited 1×
“With respect to children with obesity or NAFLD, greater quantities of Prevotella and Bacteroidetes were found matched to healthy controls [93].”
BackgroundThe gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480 · cited 1×
“This relation encloses reciprocal cellular and molecular interactions in which diet, genetic, and environmental cues are key players [1].”
BackgroundMechanisms of action of probiotics
Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019) · Advances in Nutrition · doi:10.1093/advances/nmy063 · Cited by 1,423
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Kelly, J. R., Kennedy, P. J., Cryan, J. F., Dinan, T. G., Clarke, G., & Hyland, N. P. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00392 · Cited by 1,110
Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883 · cited 1×
“This could include bacteria, archaea, fungi, protozoa, and, more recently, viruses [31].”
BackgroundIntestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749 · cited 1×
“Among others, some extensively reported examples of pathological conditions in which microbiota play a role are cardiovascular disease [32], obesity-associated comorbidities, type 2 diabetes (T2D), and NAFLD [38,39].”
BackgroundThe bowel and beyond: The enteric nervous system in neurological disorders
Rao, M., & Gershon, M. D. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.107 · Cited by 629 · cited 1×
“PAMPs release also affects other organs, including the brain and kidney [64,65].”
BackgroundClark, A., & Mach, N. (2016) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-016-0155-6 · Cited by 583
Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551 · cited 1×
“It is known that an increment in permeability in the intestine and the translocation of bacteria could facilitate that microbial metabolites getting to the liver, leading to the impairment of bile acids metabolism and the promotion of both systemic inflammation and gut dysmotility [6].”
BackgroundArchitecture of tight junctions and principles of molecular composition
Van Itallie, C. M., & Anderson, J. M. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.08.011 · Cited by 544
Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer
Singh, V., Yeoh, B. S., Chassaing, B., Xiao, X., Saha, P., Aguilera Olvera, R., Lapek, J. D., Zhang, L., Wang, W.-B., Hao, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.004 · Cited by 532
Mailing, L. J., Allen, J. M., Buford, T. W., Fields, C. J., & Woods, J. A. (2019) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000183 · Cited by 521
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention
Liu, Y., Wang, Y., Ni, Y., Cheung, C. K. Y., Lam, K. S. L., Wang, Y., Xia, Z., Ye, D., Guo, J., Tse, M. A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.001 · Cited by 405
The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
Srikantha, P., & Mohajeri, M. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092115 · Cited by 400
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394 · cited 1×
“In this line, fermentation of protein and amino acids by gut bacteria can generate excessive amounts of potentially toxic compounds such as ammonia [66].”
BackgroundEndurance exercise and gut microbiota: A review
Mach, N., & Fuster-Botella, D. (2017) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2016.05.001 · Cited by 361
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354 · cited 3×
“Hence, microbe-derived compounds and the signaling routes they influence could be implied in the progress of liver disease, especially NAFLD [72].”
BackgroundInfluentialBreast Cancer and Its Relationship with the Microbiota
Fernández, M. F., Reina-Pérez, I., Astorga, J. M., Rodríguez-Carrillo, A., Plaza-Díaz, J., & Fontana, L. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081747 · Cited by 350
Self-citationChen, P., Stärkel, P., Turner, J. R., Ho, S. B., & Schnabl, B. (2015) · Hepatology · doi:10.1002/hep.27489 · Cited by 312 · cited 2×
“It has been also reported that products in microbial translocation trigger an hepatic inflammatory response that contributes to steatohepatitis [76].”
BackgroundSchwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice
Ritze, Y., Bárdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., & Bischoff, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080169 · Cited by 292
Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
Luther, J., Garber, J. J., Khalili, H., Dave, M., Bale, S. S., Jindal, R., Motola, D. L., Luther, S., Bohr, S., Jeoung, S. W., et al. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.01.001 · Cited by 286 · cited 1×
“1% of patients with NAFLD (n = 128) had augmented gut permeability [91].”
BackgroundDysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. (2014) · Hepatology · doi:10.1002/hep.26695 · Cited by 279
Slyepchenko, A., Maes, M., Jacka, F. N., Köhler, C. A., Barichello, T., McIntyre, R. S., Berk, M., Grande, I., Foster, J. A., Vieta, E., et al. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448957 · Cited by 278
Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut · doi:10.1136/gut.2008.151977 · Cited by 273
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Methods to determine intestinal permeability and bacterial translocation during liver disease
Wang, L., Llorente, C., Hartmann, P., Yang, A.-M., Chen, P., & Schnabl, B. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.12.015 · Cited by 257 · cited 6×
“The liver is therefore the first organ in the body to have contact with PAMPs [62].”
BackgroundInfluentialScorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.031 · Cited by 237
Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology
Chen, Y., Ji, F., Guo, J., Shi, D., Fang, D., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep34055 · Cited by 205
Damms-Machado, A., Louis, S., Schnitzer, A., Volynets, V., Rings, A., Basrai, M., & Bischoff, S. C. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.131110 · Cited by 195
Alcohol or gut microbiota: who is the guilty?
Meroni, M., Longo, M., & Dongiovanni, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184568 · Cited by 183 · cited 1×
“, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma [15], being the final-stage liver disease, one of the most common causes of morbidity and mortality worldwide [16].”
BackgroundGut-Liver Axis and Sensing Microbes
Szabo, G., Bala, S., Petrasek, J., & Gattu, A. (2010) · Digestive Diseases · doi:10.1159/000324281 · Cited by 179
Maccioni, L., Gao, B., Leclercq, S., Pirlot, B., Horsmans, Y., De Timary, P., Leclercq, I., Fouts, D., Schnabl, B., & Stärkel, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1782157 · Cited by 174 · cited 1×
“The bacterial species related to these changes include Streptococcus, Shuttleworthia, and Rothia [96].”
BackgroundFaecal bacterial and short-chain fatty acids signature in hypercholesterolemia
Granado-Serrano, A. B., Martín-Garí, M., Sánchez, V., Riart Solans, M., Berdún, R., Ludwig, I. A., Rubió, L., Vilaprinyó, E., Portero-Otín, M., & Serrano, J. C. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-38874-3 · Cited by 169 · cited 1×
“Acetate is an important product of carbohydrate fermentation of most anaerobic bacteria, whereas propionic and butyric acids are produced from carbohydrate or protein fermentation through a different subdivision of bacteria [40,41].”
BackgroundRiva, A., Patel, V., Kurioka, A., Jeffery, H. C., Wright, G., Tarff, S., Shawcross, D., Ryan, J. M., Evans, A., Azarian, S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314458 · Cited by 150
Tedesco, D., Thapa, M., Chin, C. Y., Ge, Y., Gong, M., Li, J., Gumber, S., Speck, P., Elrod, E. J., Burd, E. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.019 · Cited by 137
Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.073 · Cited by 123 · cited 1×
“G-protein-coupled bile acid receptor 1 (or TGR5), which control the enterohepatic distribution [70].”
BackgroundMicrobiota modification by probiotic supplementation reduces colitis associated colon cancer in mice
Mendes, M. C. S., Paulino, D. S., Brambilla, S. R., Camargo, J. A., Persinoti, G. F., & Carvalheira, J. B. C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i18.1995 · Cited by 116
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82 · cited 1×
“After antibiotic treatment, these changes were abridged, and unfavorable effects were reestablished [79].”
BackgroundRainer, F., Horvath, A., Sandahl, T. D., Leber, B., Schmerboeck, B., Blesl, A., Groselj‐Strele, A., Stauber, R. E., Fickert, P., Stiegler, P., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14474 · Cited by 65
Microbiota and muscle highway — two way traffic
Hawley, J. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0291-6 · Cited by 57
Hernández, A., Reyes, D., Geng, Y., Arab, J. P., Cabrera, D., Sepulveda, R., Solis, N., Buist-Homan, M., Arrese, M., & Moshage, H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165857 · Cited by 42 · cited 1×
“shed light about the possibility that hypoxia could contribute to its progression in a patient with obstructive sleep apnea syndrome [53].”
Background
Cited by
Next generation probiotics for human health: An emerging perspective
Jan, T., Negi, R., Sharma, B., Kumar, S., Singh, S., Rai, A. K., Shreaz, S., Rustagi, S., Chaudhary, N., Kaur, T., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35980 · Cited by 95
“Microbiota based strategies are employed to improve intestinal barrier integrity, reduce inflammation, and ameliorate various diseases [145].”
BackgroundUnderstanding the Functionality of Probiotics on the Edge of Artificial Intelligence (AI) Era
Asar, R., Erenler, S., Devecioglu, D., Ispirli, H., Karbancioglu-Guler, F., Ozturk, H. I., & Dertli, E. (2025) · Fermentation · doi:10.3390/fermentation11050259 · Cited by 37
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
Gut Microbiota Modulation of Short Bowel Syndrome and the Gut–Brain Axis
Carter, J., Bettag, J., Morfin, S., Manithody, C., Nagarapu, A., Jain, A., Nazzal, H., Prem, S., Unes, M., McHale, M., et al. (2023) · Nutrients · doi:10.3390/nu15112581 · Cited by 21
“An increase in permeability can also drive endotoxin mediated hepatic and systemic inflammatory responses [53,54].”
BackgroundLee, S. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2584495 · Cited by 8
Metadata
- Authors
- Plaza-Díaz, J., Solís-Urra, P., Rodríguez-Rodríguez, F., Olivares-Arancibia, J., Navarro-Oliveros, M., Abadía-Molina, F., & Álvarez-Mercado, A. I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-07
- Volume
- 21
- Issue
- 21
- Pages
- 8351
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3096257404
- Cited by
- 145
- References
- 53
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.